| h-61196ade | TREM2-Dependent Microglial Senescence Transition | 0.62 | 0.55 | TREM2 | promoted | 2026-04-02 | SDA-BIOMNI-SCRNA_AN-248caecc |
| h-a01166ee | BH4 Cofactor Restoration as Primary Driver of >500-Fold Dopamine Elevation | 0.62 | 0.45 | GCH1, TH, BH4 pathway | proposed | 2026-04-13 | SDA-2026-04-13-gap-pubmed-20260410-145531-5c4e7b59 |
| h-630942bd30 | PDGF-BB/PDGFRβ/STAT3 Paracrine Signaling Axis Mediates Aβ-Induced SPP1 Upregulat | 0.62 | 0.58 | SPP1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-5e49e14f |
| h-c6c1143bcd | Complement Cascade Specificity: Microglial C3aR Antagonism Downstream of SPP1 | 0.62 | 0.58 | C3/C3aR | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062118-2cdbb0dd |
| h-b234254c | TREM2-mediated microglial tau clearance enhancement | 0.62 | 0.52 | TREM2 | archived | 2026-04-02 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-69d383ea | Low Complexity Domain Cross-Linking Inhibition | 0.62 | 0.30 | TGM2 | debated | 2026-04-02 | sda-2026-04-01-gap-006 |
| h-e20cf87fb3 | LRP1/NLRP3/IL-1β Cascade Links Aβ Endocytosis to Inflammasome Activation and SPP | 0.62 | 0.52 | SPP1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-5e49e14f |
| h-8f9633d9 | Perinatal Immune Challenge Prevention | 0.62 | 0.20 | Multiple | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-80ff3fd6 | Spatially-Targeted Regional Vulnerability Prevention | 0.62 | 0.40 | Regional vulnerability genes | proposed | 2026-04-13 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-ba11ca72 | NAMPT-Centered NAD+ Restoration to Reverse Basal Forebrain Cholinergic Neuron Me | 0.62 | 0.65 | NAMPT,SIRT1,PGC1A | proposed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d |
| h-e8d49d4cbc | MFN2-PACS2 Axis at MAMs Coordinates Mitophagy-ER-Phagy Sync | 0.61 | 0.60 | MFN2 (MFN2), PACS2 (PACS2) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062132-e71b3ef7 |
| h-b47073b186 | Glial-Autophagy-Senescence Coupling Defines CNS Therapeutic Windows | 0.61 | 0.55 | TFEB, MAPK14, MAPKAPK2, IL6, CXCL1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062101-724971bc |
| h-5e85ca4f | Dose-Response Framework: PINK1/Parkin Mitophagy as the Critical Mediator Linking | 0.61 | 0.60 | PINK1 | proposed | 2026-04-17 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-fe1dfe730e | Mitophagy collapse via PINK1-PRKN is the primary autophagy lesion after irradiat | 0.61 | 0.56 | PINK1 | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-193006-9525a13b-debate |
| h-8f285020 | Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade | 0.61 | 0.30 | AGER | proposed | 2026-04-02 | SDA-2026-04-01-gap-20260401-225149 |
| h-297a9dcbfa | FUS Mutations Alter Stress Granule Material Properties to Confer Autophagy Resis | 0.61 | 0.62 | FUS | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041423-3a6aa4ab |
| h-3a4f2027 | Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting | 0.61 | 0.50 | HTT, DMPK, repeat-containing transcripts | proposed | 2026-04-02 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| h-24e08335 | Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineeri | 0.61 | 0.30 | TDC | proposed | 2026-04-02 | SDA-2026-04-01-gap-20260401-225149 |
| h-50a535f9 | SIRT6-NAD+ Axis Enhancement Therapy | 0.61 | 0.30 | SIRT6 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-bc5f270e |
| h-a8165b3b | Complement-Mediated Synaptic Pruning Dysregulation | 0.61 | 0.50 | C1QA | proposed | 2026-04-02 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-5779a65ad4 | Cell-state stratification is required to resolve DPP6 GWAS Signal: Cell-Type Reg | 0.61 | 0.58 | GWAS | proposed | 2026-04-28 | 457c5bc3-21d8-42a3-bb99-b0fc6f3f9554 |
| h-14362edf60 | Cell-state stratification is required to resolve Proteogenomic Network Hubs as D | 0.61 | 0.58 | | proposed | 2026-04-28 | 8ec36980-febb-4093-a5a1-387ea5768480 |
| h-879492865f | Cell-state stratification is required to resolve Causal Sequence of TDP-43 Nucle | 0.61 | 0.58 | ALS | proposed | 2026-04-28 | 0ed3c364-07fd-4620-8e90-8bd33c14e370 |
| hyp_test_c201b8c0 | Test: TREM2 enhances amyloid clearance | 0.61 | 0.27 | TREM2 | proposed | 2026-04-17 | test-hypothesis-fixtures-v1 |
| h-060fcd7297 | Cell-state stratification is required to resolve Non-Neuronal Transcriptional Ch | 0.61 | 0.58 | APOE | proposed | 2026-04-28 | db9a224d-3ebb-429c-8f02-b703d71ca211 |
| h-53a96467cb | Cell-state stratification is required to resolve CCL2-CCR2 Axis at NMJ: Mechanis | 0.61 | 0.58 | NMJ | proposed | 2026-04-28 | f7f8019f-08f6-428b-adff-85e8ea202b60 |
| h-2352580bf5 | Cell-state stratification is required to resolve Genetic Aging Landscape Variant | 0.61 | 0.58 | | proposed | 2026-04-28 | bf5094c7-8ae0-4331-9871-d6f3078387c5 |
| h-509c8f986c | Cell-state stratification is required to resolve Biophysical Determinants Shifti | 0.61 | 0.58 | TDP-43 | proposed | 2026-04-28 | 52661eaf-79f8-4647-8f48-3389f5af4d59 |
| h-ccf142ff65 | Cell-state stratification is required to resolve m6A RNA Modification and Alpha- | 0.61 | 0.58 | RNA | proposed | 2026-04-28 | b7f886d9-da3f-4e0d-a8a8-9c262e268796 |
| h-5d6faf1d9e | Cell-state stratification is required to resolve Sex-Specific Microglial States | 0.61 | 0.58 | | proposed | 2026-04-28 | dfb32151-9c40-452d-8063-0c57bae5c3d6 |
| h-3941ee023b | Cell-state stratification is required to resolve Cell-Autonomous vs Non-Cell-Aut | 0.61 | 0.58 | FUS- | proposed | 2026-04-28 | 687fb884-6d31-47c3-a83f-074bad980db6 |
| h-d92beb28e8 | Cell-state stratification is required to resolve VEGF Family GWAS Signals and Ce | 0.61 | 0.58 | GWAS | proposed | 2026-04-28 | a7f528aa-20c4-409d-a8c3-e2662850e63d |
| h-494861d2 | Synaptic Pruning Precision Therapy | 0.61 | 0.70 | C1QA, C3, CX3CR1, CX3CL1 | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-62c78d8b | CaMKII-Dependent Synaptic Circuit Amplification | 0.61 | 0.65 | CAMK2A | proposed | 2026-04-04 | SDA-2026-04-03-26abc5e5f9f2 |
| h-f1f1b53e9e | HDAC3-Dependent A1 Astrocyte Commitment Window | 0.61 | 0.65 | HDAC3 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062039-7ef9980b |
| h-29ef94d5 | Epigenetic Memory Reprogramming for Alzheimer's Disease | 0.61 | 0.50 | BDNF, CREB1, synaptic plasticity genes | proposed | 2026-04-02 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| h-69bde12f | APOE4-Lipid Metabolism Correction | 0.61 | 0.40 | APOE | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-a98c87836b | Blocking Tau Packaging into Small Extracellular Vesicles via ESCRT-III Pathway | 0.61 | 0.62 | PDGRIP1L (ALIX) | proposed | 2026-04-22 | SDA-2026-04-04-gap-tau-prion-spreading |
| h-6d411c20 | GDNF Gradient Establishment by Schwann Cells Enables Motor Re-innervation | 0.61 | 0.75 | GDNF | promoted | 2026-04-14 | SDA-2026-04-14-gap-pubmed-20260410-181356-57d1f917 |
| h-7533f6ac3b | Female microglia exhibit heightened complement gene expression and pruning capac | 0.61 | 0.68 | ESR2 (NR3A2), KDM6A (UTX), C1QA, C1QB, NFKB1 | proposed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| h-6b814d561d | The most realistic translational use of physiological SCFAs is as an adjunct to | 0.61 | 0.49 | GLP1R/NLRP3 | proposed | 2026-04-24 | SDA-2026-04-25-gapdebate-18cce7b525 |
| h-ca624bf065 | Astrocyte LRP1-mediated tau uptake and APOE4-dependent secretion creates regiona | 0.61 | 0.63 | LRP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062052-946439a8 |
| h-c157796b69 | Tau Cross-Seeding and Interaction | 0.61 | 0.68 | MAPT | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a |
| h-8a16a3f363 | NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1β Suppression | 0.61 | 0.65 | NLRP3 | proposed | 2026-04-28 | SDA-TEST-PREREG-003 |
| h-0ed345d73f | H1: Senolytic Clearance of Senescent APOE4 Astrocytes | 0.61 | 0.68 | CDKN2A (p16Ink4a) | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0 |
| h-4c4e39230f | H2: H3K9me3 Heterochromatin Collapse Enables Cryptic Transcription of Repetitive | 0.61 | 0.68 | SUV39H1, CBX5 (HP1α), H3K9me3 mark | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-120802 |
| h-4805632af8 | H2: Perforant Path Synapse Loss via Early Complement Cascade Activation | 0.61 | 0.62 | C1QA, C1QB, C3, ITGAM | proposed | 2026-04-22 | SDA-2026-04-02-gap-ec-layer2-vulnerability |
| h-ab836ca0c7 | TREM2-SYK microglial activation as a stage-specific Alzheimer's disease modifier | 0.61 | 0.72 | TREM2; SYK | proposed | 2026-04-29 | SDA-2026-04-29-gap-test-20260425-224949 |
| h-55bc3e94f8 | C1q effector output is determined more by binding partner identity than by subce | 0.61 | 0.58 | C1QA,C1QB,C1QC,NPTX1,NPTX2,APP,C3 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-afba1a80bd |
| h-753ee7a30b | APOE4 preferentially signals through LRP1 over LDLR, altering endosomal choleste | 0.61 | 0.62 | LRP1, NPC1, CTSD | proposed | 2026-04-22 | SDA-2026-04-04-gap-apoe4-lipid-metabolism |